Long-term use of atomoxetine in pediatric attention deficit hyperactivity disorder (ADHD) is safe and well-tolerated, researchers report.
The results of an open-label extension study led by M.Y. Hill of Eli Lilly and Company, Indianapolis, Indiana, United States, were presented at the 12th World Conference of Psychiatry in Yokohama, Japan.
Researchers enrolled 325 subjects, 266 males, 59 females, aged from seven to 17 years old. Only patients from previous atomoxetine trials were allowed to enroll in this long-term study. All met DSM-IV criteria for ADHD from their previous atomoxetine trial.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!